Medigen Biotechnology Corp. (TPEX:3176)

Market Cap	4.21B -16.0%
Revenue (ttm)	1.59B +12.3%
Net Income	-105.96M
EPS	-0.76
Shares Out	139.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,545
Average Volume	315,927
Open	30.50
Previous Close	30.20
Day's Range	29.75 - 30.50
52-Week Range	23.65 - 36.55
Beta	0.39
RSI	35.91
Earnings Date	Mar 27, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2024, Medigen Biotechnology's revenue was 1.37 billion, an increase of 18.57% compared to the previous year's 1.16 billion. Losses were -204.69 million, -63.53% less than in 2023.